{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"condition":["Colorectal Cancer Metastatic","Colorectal Neoplasms","Unresectable Wild-Type KRAS Metastatic Colorectal Cancer","Metastatic colorectal cancer"],"disease":["Unresectable Wild-type Kras Metastatic Colorectal Cancer","Metastatic Colorectal Cancer","Colorectal Neoplasms","Colorectal Cancer Metastatic"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2149166"],"location":["Austria","Belgium","Ireland","Italy","Israel","France","Spain"],"study_start_month":["10"],"keyword":["capecitabine","fluorouracile","Irinotecan","Panitumumab","Wild-type RAS metastatic colorectal cancer","oxaliplatin","Cetuximab","lévofolinate de calcium","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"additional_accession":[]},"is_claimable":false,"name":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","description":"STRATEGIC-1 is a study designed to determine the best sequence of therapy in patients with metastatic colorectal cancer.","dates":{"creation":"2013-10-15"},"accession":"2149166","cross_references":{"ClinicalTrials___gov":["NCT01910610"],"EU Clinical Trials Register":["2013-001928-19"]}}